Immunovia AB | Lund is a revolutionary diagnostic company focused on advancing the field of blood-based diagnostics to improve patient survival rates in cancer. With a vision to transform the way diseases are detected, Immunovia offers cutting-edge products and services. Their flagship product, IMMray™ PanCan-d, is a groundbreaking blood test designed specifically for the early detection of pancreatic cancer.

Powered by the innovative IMMray™ platform, this test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d began in August 2021 in the USA, exclusively through Immunovia, Inc. Immunovia is committed to making their advanced diagnostic tools accessible to all high-risk pancreatic cancer groups.

By collaborating and engaging with healthcare providers, experts, and patient advocacy groups worldwide, they ensure the widespread availability of their tests. Since 2016, Immunovia has been leading a prospective clinical validation program involving 30 hospitals and over 10,000 patients from the USA and Europe, further advancing their mission to combat pancreatic cancer. For more information and to stay updated with their latest developments, visit www.

immunoviainc. com. Immunovia AB | Lund is dedicated to revolutionizing diagnostics and improving patient outcomes, particularly in the battle against pancreatic cancer, the world's largest market for detection